1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Celyad VP On IP Issues, Development Timelines For CAR-T Therapies

 
• By Lucie Ellis-Taitt

Georges Rawadi, vice president of business development and intellectual property at Celyad, talks to Scrip on the sidelines of the recent BIO-Europe Spring partnering conference in Barcelona about the company's pipeline of CAR-T therapies and recently resolved patent disputes for its technology.

Video interview
Celyad's George Rawadi talks to Scrip

Georges Rawadi, vice president of business development and intellectual property at Celyad SA, discusses the company's chimeric antigen receptors T- cells (CAR-T) pipeline, recently resolved IP issues and the firm's strategy for future clinical development.

On the sidelines of the recent BIO-Europe Spring partnering meeting, held in Barcelona, Mar. 20-22, Rawadi talks about how Celyad's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

Finance Watch: Lila Sciences Raises $235m To Refine Its AI Factories For Drugs And More

 
• By Mandy Jackson

Private Company Edition: Flagship’s Lila secures big series A cash six months after $200m seed funding announced in March. Also, Reunion Neuroscience increases its series A to $133m, Dualitas launches with $65m and Tasca grows its series A to $67m as its lead drug enters Phase I/II.

Ollin Launches With $100m, Two Eye Drugs And Plans To Acquire More

 
• By Mandy Jackson

The start-up, which spent two years operating in stealth mode, has a clinical-stage anti-VEGF/Ang2 drug to rival Roche’s Vabysmo, and is on the hunt for additional ophthalmology assets.

Corstasis Exploring All Options For Launch Of Enbumyst

 
• By Jessica Merrill

The nasal spray formulation of bumetanide was approved by the US FDA for edema associated with congestive heart failure and hepatic and renal disease.

PulseSight Therapeutics Builds Non-Viral Gene Therapy Pipeline For AMD

 
• By Sushmita Panda

Emerging company profile: PulseSight Therapeutics is developing non-viral gene therapies for AMD, led by PST-611 for geographic atrophy. Its electro-transfection platform aims for durable protein expression and reduced injection frequency.

More from Business

Publisher’s Spotlight: Shortlist Unveiled For Citeline Japan Awards

 
• By Ian Haydock

Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!

Asia Deal Watch: Aditum Founds Kalexo With Mabwell To Develop Dual-Target SiRNA Asset

 
• By Joseph Haas, Xu Hu, Anju Ghangurde, Vibha Ravi, and Lisa Takagi

Plus deals involving Adagene/Exelixis, Biocytogen/Tubulis, Kwangdong/Ocugen, Dr. Reddy’s/J&J, Zydus/Synthon, Stallergenes/Nuance, Argo/Novartis, XW Pharma/Avadel, Biocytogen/Merck & Co., JCR/Medipal, Novatim/Radiance and more.

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.